FY2024 Earnings Forecast for IN8bio Issued By HC Wainwright

IN8bio, Inc. (NASDAQ:INAB) – HC Wainwright issued their FY2024 EPS estimates for shares of IN8bio in a report released on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.59) for the year. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($0.52) per share. HC Wainwright also issued estimates for IN8bio’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.26) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.17) EPS and FY2028 earnings at $0.54 EPS.

IN8bio Stock Performance

Shares of INAB opened at $0.34 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.66 and a current ratio of 1.84. The company has a market cap of $15.69 million, a price-to-earnings ratio of -0.45 and a beta of -0.07. The stock has a fifty day moving average price of $0.30 and a two-hundred day moving average price of $0.67. IN8bio has a 52-week low of $0.22 and a 52-week high of $2.48.

IN8bio (NASDAQ:INAB) last posted its earnings results on Tuesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01).

Institutional Inflows and Outflows

A hedge fund recently raised its stake in IN8bio stock. Sigma Planning Corp grew its stake in IN8bio, Inc. (NASDAQ:INAB) by 42.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 851,280 shares of the company’s stock after acquiring an additional 251,600 shares during the period. Sigma Planning Corp owned 1.82% of IN8bio worth $230,000 as of its most recent filing with the Securities and Exchange Commission. 92.05% of the stock is currently owned by institutional investors and hedge funds.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.